Financial Performance - In Q1 2023, the company achieved operating revenue of 5.02 billion CNY, a year-on-year increase of 11.76% [1] - The net profit attributable to shareholders was 7,689.05 million CNY, reflecting a growth of 37.39% compared to the same period last year [1] - The net profit after deducting non-recurring gains and losses was 6,895.18 million CNY, up by 26.57% year-on-year [1] Product Sales Breakdown - Sales revenue from the main product, Losofen Sodium Gel, was 246 million CNY, a decrease of 5.64% from 261 million CNY in Q1 2022 [2] - Oral formulations generated sales revenue of 153 million CNY, showing a year-on-year growth of 26.85% [2] - Raw materials achieved sales revenue of 31.87 million CNY, with a year-on-year increase of 39.91% [2] - Pharmaceutical excipients reported sales revenue of 49.22 million CNY, up by 53.15% year-on-year [2] - Plant extracts and others generated sales revenue of 16.77 million CNY, reflecting a growth of 35.13% [2] Market Share and Product Structure - The proportion of Losofen in total revenue decreased from 58.13% to 49.08%, while oral formulations' share increased from 26.81% to 30.34% [2] - The overall gross margin for Q1 2023 was 74.91%, down from 79.1% in the previous year, attributed to changes in product structure [2] Clinical Development and Future Products - The company is actively developing multiple external use formulations, with several products in clinical trials [3] - The market for external patch agents was approximately 15 billion CNY in 2020, growing to about 18 billion CNY in 2021, with a growth rate of around 20% [3] - The company plans to invest in R&D, with expectations of approximately 10 new products being approved annually over the next 2-3 years [4]

Financial Performance - Total operating revenue for Q1 2023 reached ¥501,873,303.51, an increase of 11.6% compared to ¥449,062,914.36 in the same period last year[10] - The company's operating revenue for the current period was ¥501,873,303.51, representing an increase of 11.76% compared to the same period last year[11] - Net profit attributable to shareholders was ¥76,890,546.67, reflecting a growth of 37.39% year-over-year[11] - The net profit after deducting non-recurring gains and losses was ¥68,951,769.31, up by 26.57% from the previous year[11] - Basic and diluted earnings per share were both ¥0.22, marking a 29.41% increase year-over-year[11] - The company's operating profit for the current period was ¥85,861,272.00, an increase from ¥62,420,990.62 in the same period last year[20] Cash Flow - The net cash flow from operating activities reached ¥98,228,739.03, a significant increase of 5,414.59% compared to the same period last year[11] - The net cash flow from operating activities for the first quarter was ¥98,228,739.03, a significant increase of 5,414.59% compared to the previous period's net cash flow of -¥1,848,282.70[33] - The net cash flow from investing activities was -¥133,995,556.50, a decline of 258.52% compared to the previous period's net cash flow of ¥84,526,583.21, mainly due to increased long-term asset investments[33] - The net cash flow from financing activities was ¥47,040,354.71, a significant increase of 1,267.54% from the previous period's net cash flow of -¥4,029,029.69, primarily due to increased project loans[33] Assets and Liabilities - Total assets as of March 31, 2023, were ¥2,440,348,127.68, compared to ¥2,299,671,112.18 at the start of the year, reflecting a growth of 6.1%[9] - Total liabilities increased to ¥798,462,601.25 from ¥747,050,467.29, marking a rise of 6.5%[9] - The company's inventory as of Q1 2023 was ¥278,058,701.01, up from ¥241,039,257.35, indicating a growth of 15.3%[6] - Short-term borrowings rose to ¥81,394,373.89 from ¥71,568,322.23, an increase of 13.0%[9] - Total cash and cash equivalents at the end of the period amounted to ¥346,323,811.83, down from ¥455,046,435.86 in the previous period[31] Equity - The total equity attributable to shareholders reached ¥1,641,885,526.43, up from ¥1,552,620,644.89, reflecting a growth of 5.7%[9] - The total equity attributable to shareholders was ¥1,641,885,526.43, reflecting a growth of 5.75% compared to the previous year[11] Expenses - Research and development expenses increased to ¥42,597,978.69, compared to ¥34,289,853.06 in the previous year[20] - Operating costs increased to ¥125,938,556.98, reflecting a 34.17% rise compared to ¥93,861,775.81 in the previous period, primarily due to changes in revenue and product mix[33] - Management expenses surged by 78.47% to ¥19,361,866.30, up from ¥10,848,534.97, mainly due to increased equity incentive costs[33] - The company reported a 41.47% increase in income tax expenses to ¥8,983,704.23, up from ¥6,350,186.61, due to increased profits[33] Shareholder Information - The company reported a total of 3,154,206 shares held by individual shareholder Lü Jubao, representing 0.92% of total shares[36] - Major shareholders include Zhu Zhihong with 29,368,500 shares and a significant stake held by various investment funds[36] - The company has not disclosed any relationships or concerted actions among the top shareholders[36] Audit and Compliance - The first quarter report has not been audited, ensuring the financial data's integrity[46] - The company guarantees the accuracy and completeness of the quarterly report, with all board members assuming legal responsibility[42] - There are no adjustments or restatements required for previous accounting data[47] Government Subsidies - The company received government subsidies amounting to ¥9,038,368.49 during the current period[12] - The company received government subsidies, contributing to a 582.44% increase in other income to ¥9,223,493.74 from ¥1,351,554.00 in the previous period[33]

湖南九典制药股份有限公司 投资者关系活动记录表 证券代码：300705 证券简称：九典制药 编号：2023-11 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 人员姓名 九典制药 2022 年度业绩说明会采用网络远程方式进行，面向 全体投资者 时间 2023 年 4 月 18 日下午 15:00-17:00 地点 公司会议室 上市公司接待人 员姓名 总经理：郑霞辉 独立董事：阳秋林 副总经理兼董事会秘书：曾蕾 财务总监：熊英 保荐代表人：江伟 投资者关系活动 主要内容介绍 主要采用解答投资者提问的方式进行，问题回复如下： 1、公司年度经营情况？ 回复：尊敬的投资者，您好！2022 年公司以市场为中心， 积极推进营销模式升级，销售取得新突破。全年实现营业收 入 23.26 亿元，同比增长 42.92%；归属于上市公司股东的净 利润 2.7 亿元，同比增长 32.05%；归属于上市公司股东的扣 非后净利润 2.48 亿元，同比增长 37.80%。详细内容可参考公 司披露的 2022 年年度报告。感谢您对公司的关注！ 2、公 ...

Employee Training and Development - The company has implemented a comprehensive training system, focusing on leadership training for senior management and skill enhancement for technical staff, aiming to improve overall employee quality [3]. - The company has focused on enhancing employee skills through various training programs, including safety production and quality control [3]. - The company has implemented a performance evaluation system for employee recruitment, training, and benefits, ensuring compliance with labor laws [26]. Environmental Compliance and Protection - The company adheres to environmental standards, treating wastewater before discharge and complying with relevant pollution discharge standards [14]. - The company is actively monitoring and updating its compliance with environmental protection laws and regulations [16]. - The company has committed to environmental governance by increasing investment in environmental protection and regularly paying environmental protection taxes [24]. - The company has a monitoring plan in place for environmental self-monitoring to ensure compliance with pollution discharge standards [23]. - The company has established a comprehensive system for monitoring COD and pH levels in its environmental workshop [21]. - The total COD emissions are capped at 4.92 tons per year, and ammonia nitrogen emissions are limited to 0.79 tons per year, with a wastewater treatment capacity of 350 tons per day [21]. - The company has signed a self-monitoring contract with a testing technology company to ensure compliance with pollution discharge standards [45]. - The company’s emissions of volatile organic compounds (VOCs) were recorded at 0.422 tons, adhering to the set standards [41]. - The company is committed to environmental protection and may face increased operational costs due to stricter environmental regulations in the future [118]. Financial Performance and Profit Distribution - The company has a profit distribution plan that complies with its articles of association, including cash dividend policies [4]. - The company reported a revenue of 60 million yuan for the current fiscal year, with an audit service duration of 8 years by the accounting firm Zhongzheng Zhonghuan [33]. - The profit distribution plan approved by the board proposes a cash dividend of 2.36 CNY per 10 shares, based on a total of 342,936,227 shares [118]. - The company’s total revenue for 2022 was 2,326,205,867.76 CNY, with a year-on-year increase of 46.57% in sales expenses due to intensified market expansion efforts [137]. - The net profit attributable to shareholders for Q4 2022 was 61,310,862.37 CNY, while the total net profit for the year was 269,700,251.55 CNY, reflecting a strong performance despite market challenges [127]. - The company reported a non-operating income of approximately 21.49 million in 2022, a decrease from 24.12 million in 2021 [73]. Market Position and Product Development - The company has plans for future market expansion and product development, although specific details were not disclosed in the call [17]. - The company focuses on the production of active pharmaceutical ingredients (APIs) such as Secnidazole, which is used for treating various infections, and Sodium Dihydrogen Phosphate, utilized in multiple medical applications [36]. - The company has successfully filed approximately 10 new drug formulation projects annually, with 15-20 new projects initiated each year [60]. - The company has established a rich product reserve in anti-inflammatory, digestive, and anti-infection treatment areas, with notable products in each category [60]. - The company is actively engaged in CRO, CMO, and CDMO services, enhancing its core competitiveness through collaboration with pharmaceutical companies [63]. - The company has established a strong presence in the high-end excipients market, with 77 registered excipient varieties and products sold in multiple countries including India, South Korea, and Europe [63]. - The company is focusing on self-research and development, with a strong emphasis on industry-academia-research cooperation to enhance its R&D capabilities [142]. - The company has a strong focus on R&D, with nearly 100 products under development or submitted for approval, enhancing its product pipeline significantly [164]. Regulatory Compliance and Corporate Governance - There were no significant internal control deficiencies reported during the period, with zero major or important defects identified in financial reporting [11]. - The company has a robust internal control framework, with no non-standard opinions issued by the auditing firm regarding internal control audits [12]. - The company is currently fulfilling its commitments regarding corporate governance and compliance with regulatory requirements [29]. - The company has fulfilled its commitments regarding the return measures and will comply with any new regulations from the China Securities Regulatory Commission [30]. - The company has a commitment to not engage in unfair benefit transfers or misuse company assets [30]. - The company has not experienced major safety incidents since its establishment, but risks remain due to operational hazards [98]. Research and Development - The company has established a comprehensive R&D system, but faces risks related to market trend predictions and funding for development [94]. - The R&D team consists of over 400 members, primarily composed of PhDs, master's graduates, and overseas returnees [179]. - The company is focusing on developing new functional materials for transdermal drug delivery systems, addressing key technical challenges [179]. - The company is committed to ongoing research and development, with a significant number of products in the pipeline [198]. - The company is enhancing its competitive edge by securing core invention patents for its new drug formulations [198]. Sales and Marketing Strategies - The sales model includes prescription drug sales primarily through hospitals and non-prescription drug sales via retail pharmacies, employing a cooperative distribution strategy with qualified pharmaceutical companies [38]. - The marketing department is actively exploring new marketing strategies, with the sub-brand "Jiuyue" Gel Patch gaining a strong reputation for quality and clinical efficacy [194]. - The company is strategically reducing low-margin excipient sales while developing high-tech excipients to align with its focus on external preparations [194]. - The company is expanding its market presence through the analysis of product positioning across various channels, leading to improved sales performance [194]. Legal Matters - The company is currently involved in a lawsuit with a claim amount of 13 million yuan, which has not yet been fully executed [34].

湖南九典制药股份有限公司 关于举办 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 15 日在 巨潮资讯网上披露了《2022 年年度报告全文》及《2022 年年度报告摘要》。为 便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 4 月 18 日（星期二）15:00-17:00 在"价值在线"（www.ir-online.cn） 举办湖南九典制药股份有限公司 2022 年度业绩说明会，与投资者进行沟通和交 流，广泛听取投资者的意见和建议。 证券代码：300705 证券简称：九典制药 公告编号：2023-026 欢迎广大投资者积极参与。 特此公告。 湖南九典制药股份有限公司董事会 2023 年 4 月 15 日 出席本次年度业绩说明会的人员有：董事、总经理郑霞辉先生，独立董事阳 秋林女士，财务总监熊英女士，副总经理兼董事会秘书曾蕾女士及保荐代表人江 伟先生。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提 ...

Group 1: Company Overview and Product Development - The company, Hunan Jiudian Pharmaceutical Co., Ltd., began its foray into external preparation products in 2003 with the development of traditional Chinese medicine gel patches [1] - The first product, Loxoprofen Sodium Gel Patch, was approved for market in 2017, indicating a long-term experience and technical accumulation process [2] - The company has over 15 ongoing research projects focused on transdermal drug delivery, including gel patches and topical preparations [3] Group 2: Market Strategy and Impact - The implementation of collective procurement in the Guangdong Alliance region is expected to expand the sales range of Loxoprofen Sodium Gel Patch and positively impact the company's long-term development [2] - The company is actively developing various products in the local transdermal drug delivery field, with different sales strategies and pricing systems for each market segment [3] - The company aims to establish a strong product lineup and enhance brand value with the "Jiuyue" patch brand, anticipating good results in the transdermal drug delivery sector [3] Group 3: Research and Clinical Progress - The company is currently conducting clinical trials for multiple products, including Indomethacin Gel Patch and PDX-02, with several other products in preclinical research or project initiation stages [2] - The approval process for the Ketoprofen Gel Patch is ongoing, but the timeline remains uncertain due to administrative factors [2] - The company is also focusing on developing raw materials and excipients for external preparations to address key supply chain issues [3]